Biotech

All Articles

iTeos- GSK's TIGIT star presents significant remodeling

.After introducing a period 3 launch based on positive midstage results, iTeos and also GSK are fina...

More joint FDA can accelerate uncommon disease R&ampD: report

.The FDA needs to be extra available and also collaborative to release a surge in approvals of uncom...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It is actually an uncommonly occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as well as...

Atea's COVID antiviral fails to halt hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has actually failed one more COVID-19 trial, however the biotech st...

Neurocrine's proposal to conserve schizophrenia prospect falls short

.Neurocrine Biosciences' schizophrenia plan pivot has actually stopped working. The biotech was inca...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually created an overdue access to the radioligand event, paying for 100 thousand eur...

F 2G rears $100M for second effort to acquire brand-new antifungal to market

.After F2G's first attempt to get a new course of antifungal to market was derailed due to the FDA, ...

Moderna targets $1.1 B in R&ampD investing cuts, falls 5 programs among earnings pressures

.Moderna has pledged to cut R&ampD spending by $1.1 billion through 2027. The decision to retract th...

Sanofi's $80M bank on Pivot dystrophy drug ends in stage 3 crash

.Merely 4 months after Sanofi bet $80 thousand in ahead of time cash on Fulcrum Therapeutics' losmap...

Oncternal stock drains 60% amidst layoffs, trial firings

.Cancer provider Oncternal Therapeutics is actually folding all its clinical trials as well as layin...